Sasanlimab

Phase 2Monoclonal antibody

Pfizer

Sasanlimab is one of 109 biologic programs targeting Clear Cell Renal Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

108

Competitors

Pipeline

Status by Indication[3][1]

Indication

Clear Cell Renal CarcinomaRecruiting

Metastatic Renal Cell CarcinomaRecruiting

Advanced CancersActive, not recruiting

Clinical TrialActive, not recruiting

Bladder CancerActive, not recruiting

Clear Cell Renal CarcinomaPreclinical

Recruiting

Metastatic Renal Cell CarcinomaPhase 2

Recruiting

Advanced CancersPhase 1

Active, not recruiting

Clinical TrialPhase 1

Active, not recruiting

Bladder CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

136 competitors in Clinical Trial

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

3 2

Venclexta

AbbVie

Phase 3

2 3

Avelox

Bayer

Phase 3

2 4

Paraplatin

AAvyxa

Phase 3

2 5

Opzelura

DDizal Pharmaceuticals

Phase 3

1 6

Potassium Iodide

MMeda Pharmaceuticals

Phase 3

1 7

Ablysinol

CSL Behring

Phase 3

1 8

Nascobal

GGrupo Espanol de Tumores Neuroendocrinos

Phase 3

1 9

Zelboraf

CConrado Roberto Hoffmann Filho

Phase 2

1 10

FOLFOXIRI

SSun Yat-sen University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2/3Not yet recruiting

Immune Checkpoint Inhibitor

NCT06218069

Q2 2027

Phase 2Active, not recruiting

Bladder Cancer

NCT05241340

PreclinicalRecruiting

Clear Cell Renal Carcinoma

NCT05665361

Q2 2028

Phase 2Recruiting

Metastatic Renal Cell Carcinoma

NCT07123090

Q1 2033

Phase 1Recruiting

Non Muscle Invasive Bladder Cancer

NCT07206225

Clinical

Trials by Indication[1]

Bladder Cancer2 trials

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

Active, not recruiting·TThe Methodist Hospital Research Institute·Phase 2·NCT05241340·33 enrolled

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Withdrawn· Pfizer logo

Pfizer·Phase 1·NCT05259397

Cancer2 trials

A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

Terminated· Pfizer logo

Pfizer·Phase 1·NCT06546553·10 enrolled

A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

Terminated· Pfizer logo

Pfizer·Phase 1·NCT06580938·4 enrolled

Immune Checkpoint Inhibitor1 trial

Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor

Not yet recruiting·RRadboud University Medical Center·Phase 2/3·NCT06218069·20 enrolled

Advanced/Metastatic Solid Tumors1 trial

A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination

Terminated· Pfizer logo

Pfizer·Phase 1·NCT06448364·4 enrolled

Advanced Solid Tumors1 trial

A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

Terminated· Pfizer logo

Pfizer·Phase 1·NCT06285097·9 enrolled

10 more indications

Selected Advanced Solid Tumors1 trial

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Terminated· Pfizer logo

Pfizer·Phase 1·NCT05061537·13 enrolled

Metastatic Solid Tumors1 trial

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Terminated· Pfizer logo

Pfizer·Phase 1·NCT04458259·88 enrolled

Advanced Cancers1 trial

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

Active, not recruiting· Pfizer logo

Pfizer·Phase 1·NCT06870487·6 enrolled

Advanced or Metastatic Solid Tumors1 trial

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

Terminated· Pfizer logo

Pfizer·Phase 1·NCT05233436·21 enrolled

Clinical Trial1 trial

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

Active, not recruiting· Pfizer logo

Pfizer·Phase 1·NCT06974734·9 enrolled

Non-Small Cell Lung Cancer1 trial

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Terminated· Pfizer logo

Pfizer·Phase 1/2·NCT04585815·34 enrolled

Advanced Cancer1 trial

A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Terminated· Pfizer logo

Pfizer·Phase 1·NCT04254107·133 enrolled

Non Muscle Invasive Bladder Cancer1 trial

A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF PF-08052667 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 18 YEARS OF AGE AND OLDER WITH BLADDER CANCER

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT07206225·294 enrolled

Metastatic Renal Cell Carcinoma1 trial

A Phase 2 Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma - SPARCC

Recruiting·SStephanie Berg·Phase 2·NCT07123090·25 enrolled

Clear Cell Renal Carcinoma1 trial

A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT05665361·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Sasanlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sasanlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sasanlimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: Pfizer

Sasanlimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q2 2028

Q1 2033

Trials by Indication[1]

Bladder Cancer2 trials

Cancer2 trials

Immune Checkpoint Inhibitor1 trial

Advanced/Metastatic Solid Tumors1 trial

Advanced Solid Tumors1 trial

Selected Advanced Solid Tumors1 trial

Metastatic Solid Tumors1 trial

Advanced Cancers1 trial

Advanced or Metastatic Solid Tumors1 trial

Clinical Trial1 trial

Non-Small Cell Lung Cancer1 trial

Advanced Cancer1 trial

Non Muscle Invasive Bladder Cancer1 trial

Metastatic Renal Cell Carcinoma1 trial

Clear Cell Renal Carcinoma1 trial

References

Drug Info

Quick Facts

Related News